The global health and wellness industry is celebrating a historic regulatory milestone as Galway-based Chanelle McCoy Health officially secures world-first approvals for its flagship Cannabidiol (CBD) line, Pureis® Ultra Pure CBD. The company has become the first and only business globally to receive simultaneous regulatory approval for CBD as an oral food supplement from the Saudi Food and Drug Authority (SFDA) and confirmation of safety under the European Union Novel Food guidelines by European regulators.
The achievement marks a critical turning point for the highly scrutinized CBD sector, proving that with pharmaceutical-grade standards, robust clinical data, and persistent dedication to safety, CBD products can successfully navigate the world's most stringent regulatory hurdles. Co-founders Chanelle McCoy and Caroline Coen, alongside their scientific team, spent eight years, invested millions of euros in proprietary clinical research, and maintained an unshakeable belief in the science to secure this regulatory green light.
"With the right science, the right standards, and the right determination, a small Irish company can lead globally," remarked Chanelle McCoy. "Today, we have."
The Visionaries Behind the 8-Year Journey
The breakthrough is the result of a long-term vision spearhead by two prominent figures in the Irish life sciences sector: Chanelle McCoy, one of Ireland’s most successful business leaders and a former investor on Ireland's version of Dragons' Den, and Caroline Coen, a highly experienced pharmacologist. Having spent years working in traditional pharmaceuticals-where safety dossiers and clinical testing are non-negotiable-the founders recognized early on that the unregulated nature of the CBD industry was its biggest weakness.
When Chanelle McCoy Health was founded, the team set out to apply the same rigorous scientific standards used in pharma to the wellness sector. Rather than taking shortcuts or rushing plant-derived extracts to market, they opted to design a product from the ground up that could pass the toughest regulatory evaluations in the world. This meant investing heavily in proprietary toxicology studies, preclinical assessments, and clinical trials equivalent to Phase I drug testing.
The Science of Purity: Why Synthetic CBD is the Key
To navigate the regulatory pathways in both Saudi Arabia and Europe, Chanelle McCoy Health made the strategic decision to formulate Pureis® Ultra Pure CBD using lab-grown, synthetic CBD. Derived from citrus molecules rather than extracted from the hemp plant, this synthetic approach offers critical advantages that paved the way for regulatory approval:
- 0% THC Guaranteed: Unlike plant-extracted CBD, which often contains trace amounts of Tetrahydrocannabinol (THC), Pureis® contains absolutely zero THC. This makes the product completely non-addictive and non-psychoactive, allowing it to comply with strict narcotics laws, particularly in the Middle East.
- Zero Contaminants: Lab-grown synthesis eliminates the risk of heavy metals, pesticides, industrial pollutants, and agricultural contaminants that hemp plants naturally absorb from the soil.
- Batch-to-Batch Consistency: Synthesizing the active ingredient ensures that every single dose contains the exact milligram strength specified, providing a degree of quality control and dose consistency that plant extracts cannot match.
The Regulatory Double-Win: SFDA and EU Novel Food
The dual validation from Saudi Arabia and Europe represents the highest regulatory bar achieved by any CBD brand globally. Both jurisdictions maintain notoriously rigorous safety standards, but they approach food supplement governance from slightly different angles.
| Regulatory Body | Region | Approval Category | Core Compliance Thresholds |
|---|---|---|---|
| Saudi Food and Drug Authority (SFDA) | Saudi Arabia & GCC | Oral Food Supplement | Strict 0% THC mandate, chemical purity analysis, safety profile verification, and origin audit. |
| European Regulators (EFSA / EC) | European Union | Confirmed Safe (Novel Food) | Extensive GLP/OECD toxicology data package, sub-chronic toxicity studies, and genotoxicity evaluations. |
Saudi Arabia's SFDA: A Gateway to the Middle East
The Saudi Food and Drug Authority is widely regarded as one of the most conservative and demanding regulatory agencies in the world. Given the kingdom's zero-tolerance policy toward psychoactive substances, any product associated with cannabis faces immense scrutiny. By demonstrating 100% purity and a reliable synthetic origin entirely free of THC, Pureis® became the first oral CBD product to receive the SFDA's official seal of approval. This milestone serves as a regulatory template and key gateway for Chanelle McCoy Health to expand across the Gulf Cooperation Council (GCC) and the wider Middle East and North Africa (MENA) regions.
Europe's Novel Food Guidelines: A Scientific Gold Standard
In Europe, the European Food Safety Authority (EFSA) and local member state regulators oversee the approval of "Novel Foods"-ingredients that do not have a history of significant consumption in the EU before 1997. The EU Novel Food process requires manufacturers to submit exhaustive scientific dossiers detailing the compound's manufacturing process, stability, toxicology, and clinical safety. The confirmation of safety for Pureis® under these guidelines represents a massive validation of the proprietary scientific studies funded by the company, positioning it as a safe, compliant option for European consumers.
Market Launch and Global Ambitions
With these historic approvals in hand, Chanelle McCoy Health is moving swiftly into execution mode. The company is progressing with regulatory filings in over 40 other countries, leveraging the SFDA and EU validations as benchmarks of safety. Immediate launch plans are underway across multiple international markets, introducing a range of products that consumers and healthcare professionals can trust for quality, compliance, and dosing accuracy.
As the wellness sector transitions away from unregulated, ad-hoc products toward high-standard, science-backed solutions, Chanelle McCoy Health’s breakthrough stands as a prime example of how scientific rigour pays off. For the global wellness industry, the green light for Pureis® is indeed a mega moment-proving that the future of wellness is firmly rooted in safety, science, and compliance.
